CRL Stock Analysis — Charles River Laboratories
Sector: Healthcare
AI Verdict
At 20.4x forward earnings with flat growth and extreme RSI, you're paying up for a moat that needs to deliver real growth soon or risk a sharp correction.
Competitive Moat
Charles River Laboratories provides preclinical and clinical laboratory services that are deeply embedded in the drug development pipeline, making it a critical partner for pharmaceutical and biotech firms. Its moat comes from decades-long client relationships and regulatory expertise, which create high switching costs for customers reliant on consistent, compliant research support.
Summary
RSI at 85.4 signals extreme overbought territory after a 52.48% 1-year run, putting CRL in the spotlight for a potential reversal.
Where It Stands
CRL trades at 20.4x forward earnings, below the healthcare sector median of 22x, despite an RSI of 85.4 and barely positive 0.1% revenue growth.
Key Metrics
- RSI: 85.4 — Overbought
- Forward P/E: 20.4x
- Revenue Growth: +0.0%
- Market Cap: $11.3B
- 1-Year Return: 52.48%
- 52-Week High: $228.88
- 52-Week Low: $144.26
Analyst Consensus
16 Buy · 8 Hold · 0 Sell (24 analysts)
Bull Case
The 52.48% 1-year return shows strong market enthusiasm for CRL's role in the drug development ecosystem, even as it trades at a 7% discount to the sector's forward P/E.
Bear Case
With RSI at 85.4 and revenue growth stuck at 0.1%, a pullback to a sector-average P/E (22x) would mean little valuation support if momentum fades.
Catalyst to Watch
Watch for upcoming earnings or guidance updates—any sign of revenue acceleration above 0.1% could justify the premium and sustain momentum.